Letrozol Viatris

Letrozole, the active ingredient in Letrozol Viatris, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Viatris acts on estrogen‑dependent breast cancer pathways. - Adjuvant treatment of hormone receptor‑positive breast cancer in postmenopausal women: reduces risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows disease progression and improves survival. - Neoadjuvant therapy for hormone receptor‑positive breast cancer in postmenopausal women: may shrink tumor size before definitive surgery.

Letrozol Viatris may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: transient episodes of increased warmth and sweating. - Arthralgia: joint pain or stiffness, often affecting knees and hips. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Osteoporosis: decreased bone mineral density leading to fracture risk. - Venous thromboembolism: blood clots in deep veins or lungs. - Severe liver injury: marked elevation of hepatic enzymes or jaundice.

Before initiating Letrozol Viatris, consider the following safety measures. - Bone health assessment: evaluate baseline bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular monitoring: assess risk factors for thrombosis and monitor for signs of clot formation. - Liver function testing: obtain baseline hepatic enzymes and repeat periodically. - Drug interactions review: check concomitant medications for potential CYP2A6 or CYP3A4 interactions. - Pregnancy contraindication: do not use in pregnant or breastfeeding women; teratogenic risk is high. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Letrozol Viatris can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP2A6 inducers (e.g., rifampin): may markedly reduce letrozole exposure and efficacy. - Estrogen‑containing hormonal therapies: antagonize the intended estrogen‑lowering effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels, requiring monitoring for toxicity. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, necessitating INR checks. - Cholesterol‑lowering agents (e.g., statins): monitor for additive musculoskeletal complaints.